MICROPORE TECHNOLOGIES

According to the AAPS ~90% of pipeline drugs & 40% of marketed drugs are poorly water-soluble. Lipid-based formulations are preferred for formulation of nutraceuticals, vaccines, and pharmaceuticals. The number of nucleic acid therapies approved or in development, including mRNA vaccines, is growing very rapidly.

Great tribute must be paid to the hugely impressive efforts of those who reconfigured existing equipment at extraordinary speed into a “Generation 1” manufacturing process for their Covid-19 vaccines as part of the global response to the Coronavirus pandemic. However, it is unclear that this high pressure configuration is optimised to meet future needs.

Micropore offers its fully aseptic, low pressure technology to optimise the technology into a “Generation 2” configuration to improve overall efficiencies for the anticipated major growth in LNP technology as a delivery system for not only Covid vaccines but also wider treatment of other infectious diseases and cell & gene therapies for hereditary diseases. Notable features are the technology’s seamless scalability from 1 mL, for the first experiment, through to over 1,000 L/hr, for full sclae manufacturing, using the same geometry with class leading encapsulation efficiency and no mRNA degradation.

Micropore is a winner in the Pharma categories of the 2021 IChemE Global Awards for its Versatile LNP Manufacturing. We consider this application of Micropore’s technology to be the most significant yet because of its potentiial impact on humanity.

BOOK YOUR PLACE NOW

Pharma-logo-360px-1

 LIVE ONLINE

16 November 2021

CATCH UP ON DEMAND